Phase 2 N=40 Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea
Acne Rosacea
Primary: Change From Baseline in Total Lesion Count at Week 12 — -10.2; -12.0 number of lesions — p=0.366
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=94 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
Squamous Cell Carcinoma of Anal Canal
Primary: Objective Response Rate (ORR) — 13.8 percentage of participants
Phase 2 N=30 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
Metastatic Clear Cell Renal Cell Carcinoma
Primary: Response Rate — 4 Participants
Phase 2 N=480 GB001 in Adult Subjects With Moderate to Severe Asthma
Asthma
Primary: Proportion of Participants Who Experience Worsening of Asthma by Week 24 — 0.658; 0.567; 0.568; 0.557 proportion of participants — p=0.1425
Phase 2 N=66 A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
Rheumatoid Arthritis
Primary: Core Treatment Phase: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 12 Based on Non-responder Imputation (NRI)…
Phase 2 N=221 Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
COVID-19
Primary: Number of Participants Infected With COVID-19 or COVID-19 Like Illness During the Trial — 13; 32 Participants — p=0.0112
Phase 2 N=302 An Oral p38 Inhibitor Investigating Safety, Efficacy, And PK In Subjects With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20 Percent (%) (ACR 20) Response at Week 12 — 39.13; 41.89; 40.91; 40.00 percentage of participants…
Phase 2 N=47 Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.
Oropharynx Cancer
Primary: Combined AUC for Selected Patient Symptoms — 3.1; 3.7 score on a scale*week
Phase 2 N=21 Personalized Treatment Algorithms for Difficult-to-treat Asthma
Asthma in Children
Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52
Phase 2 N=81 Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
Coronary Artery Disease · Human Immunodeficiency Virus
Primary: Coronary Endothelial Function Measured by Percent Change in Coronary Blood Flow With Exercise (%) at 8 Weeks — 8.1; 13.4 Percent change from rest measurement
Phase 2 N=31 Capnometry-Assisted Breathing Training for COPD
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Adherence to Home Breathing Exercises — 10; 5 Participants
Phase 2 N=180 A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
Healthy
Primary: Hemagglutination Inhibition (HI) Antibody Titers as Measured by Hemagglutination Inhibition Assay (HAI) Against Each of the Four Vaccine Influenza Strains — 215; 168…
Phase 2 N=48 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Response Based on Overall Response Rate — 17; 11; 28; 6 Participants
Phase 2 N=43 Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
Necrotizing Soft Tissue Infections
Primary: Number of Subjects With One or More Adverse Events (AEs) During the Treatment Period — 14; 16; 9 Participants
Phase 2 N=152 An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
Graft-versus-host Disease · Acute-graft-versus-host Disease
Primary: Cumulative Incidence Percentage of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 Post-Hematopoietic Stem Cell Transplant (HSCT) — 38.4; 47.1…